Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (1)
P 4 (1)

Trial Status

Active Not Recruiting2
Not Yet Recruiting2
Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07204743Not ApplicableActive Not Recruiting

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

NCT06668389Phase 4Recruiting

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

NCT06750458Phase 3Not Yet Recruiting

Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients

NCT06759909Phase 1Not Yet RecruitingPrimary

Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation

NCT06748105Phase 2Active Not RecruitingPrimary

Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia

Showing all 5 trials

Research Network

Activity Timeline